Xbrane Biopharma Q2’22: Xlucane™ Launch Anticipated to Q1’23
Research Note
2022-07-22
13:40
Redeye comments on Xbrane Biopharma’s Q2 2022 report, which despite the recent setback, leaves us feeling encouraged ahead of the European launch of Xlucane™, anticipated in Q1 2023.
Filip Einarsson
Disclosures and disclaimers